The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection has been in shortage since 2022 due to increased demand.
administrator
Related Articles
27th Meeting of the Society of Hair Testing…
- December 13, 2025
New Metabolites of Methyldienolone by In Vitro Human Liver…
- December 12, 2025
A First Report of the Misuse of a…
- December 12, 2025